In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Type 2 diabetes mellitus constitutes approximately 90% of all reported forms of diabetes mellitus. Insulin resistance characterizes this manifestation of diabetes. The prevalence of this condition is commonly observed in patients aged 45 and above; however, there is an emerging pattern of younger cohorts receiving diagnoses primarily attributed to lifestyle-related variables, including obesity, sedentary behavior, and poor dietary choices. The enzyme SGLT2 exerts a negative regulatory effect on insulin signaling pathways, resulting in the development of insulin resistance and subsequent elevation of blood glucose levels. The maintenance of glucose homeostasis relies on the proper functioning of insulin signaling pathways, while disruptions in insulin signaling can contribute to the development of type 2 diabetes.
OBJECTIVE: Our study aimed to investigate the role of SGLT2. This enzyme interferes with insulin signaling pathways and identifies potential SGLT2 inhibitors as a treatment for managing type 2 diabetes.
METHODS: We screened the Maybridge HitDiscover database to identify potent hits followed by druglikeness, Synthetic Accessibility, PAINS alert, toxicity estimation, ADME assessment, and Consensus Molecular docking.
RESULTS: The screening process led to the identification of three molecules that demonstrated significant binding affinity, favorable drug-like properties, effective ADME, and minimal toxicity.
CONCLUSION: The identified molecules could manage T2DM effectively by inhibiting SGLT2, providing a promising avenue for future therapeutic strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Current drug discovery technologies - (2023) vom: 01. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Debnath, Abhijit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Docking |
|---|
| Anmerkungen: |
Date Revised 04.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0115701638267615231123160650 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365383295 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365383295 | ||
| 003 | DE-627 | ||
| 005 | 20231226101540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0115701638267615231123160650 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1217.xml |
| 035 | |a (DE-627)NLM365383295 | ||
| 035 | |a (NLM)38047361 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Debnath, Abhijit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Type 2 diabetes mellitus constitutes approximately 90% of all reported forms of diabetes mellitus. Insulin resistance characterizes this manifestation of diabetes. The prevalence of this condition is commonly observed in patients aged 45 and above; however, there is an emerging pattern of younger cohorts receiving diagnoses primarily attributed to lifestyle-related variables, including obesity, sedentary behavior, and poor dietary choices. The enzyme SGLT2 exerts a negative regulatory effect on insulin signaling pathways, resulting in the development of insulin resistance and subsequent elevation of blood glucose levels. The maintenance of glucose homeostasis relies on the proper functioning of insulin signaling pathways, while disruptions in insulin signaling can contribute to the development of type 2 diabetes | ||
| 520 | |a OBJECTIVE: Our study aimed to investigate the role of SGLT2. This enzyme interferes with insulin signaling pathways and identifies potential SGLT2 inhibitors as a treatment for managing type 2 diabetes | ||
| 520 | |a METHODS: We screened the Maybridge HitDiscover database to identify potent hits followed by druglikeness, Synthetic Accessibility, PAINS alert, toxicity estimation, ADME assessment, and Consensus Molecular docking | ||
| 520 | |a RESULTS: The screening process led to the identification of three molecules that demonstrated significant binding affinity, favorable drug-like properties, effective ADME, and minimal toxicity | ||
| 520 | |a CONCLUSION: The identified molecules could manage T2DM effectively by inhibiting SGLT2, providing a promising avenue for future therapeutic strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Docking | |
| 650 | 4 | |a SGLT2 | |
| 650 | 4 | |a SGLT2 inhibitor | |
| 650 | 4 | |a T2DM drugs | |
| 650 | 4 | |a Type 2 diabetes mellitus | |
| 700 | 1 | |a Sharma, Shalini |e verfasserin |4 aut | |
| 700 | 1 | |a Mazumder, Rupa |e verfasserin |4 aut | |
| 700 | 1 | |a Mazumder, Avijit |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Dua, Arpita |e verfasserin |4 aut | |
| 700 | 1 | |a Singhal, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Arvind |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Gurvinder |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug discovery technologies |d 2004 |g (2023) vom: 01. Dez. |w (DE-627)NLM160661455 |x 1875-6220 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:01 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0115701638267615231123160650 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 01 |c 12 | ||